News – Page 936 – Endpoints News

Scripps-led consortium scores $129M NIH grant to work on vaccine for stubborn HIV

6 years ago

Faced with a PhIII flop in NASH, Gilead is sequencing 15,000 patients to find new drugs

6 years ago

Analysis: In most of the Big Pharma world, R&D spending towers over revenue from new drugs. Guess who beat the odds

6 years ago

New peanut allergy therapies aren’t as effective — or nearly as inexpensive — as abstinence, says ICER

6 years ago

White House changes course to kill rebate reform

6 years ago

Can a Medicare Advantage insurer be great at drug development for their target audience?

6 years ago

GlaxoSmithKline recruits a new coach and top player for their AI/ML team out of Genentech and MIT

6 years ago

Astex vet Neil Thompson looks to build discovery from scratch at rare disease AI upstart out of Cambridge, UK

6 years ago

Sanofi begins countdown for FDA isatuximab review; Cirrhosis-focused biotech presents another mini IPO

6 years ago

Genmab steps up for a $500M IPO haul, with its sights on a record-setting market cap

6 years ago

Supply constraints push EpiPen rival maker Amneal to restructure, shares fall

6 years ago

The FDA's Janet Woodcock talks about some big changes she's pushing for in drug development, and agency reviews

6 years ago

Fresh out of beleaguered Merrimack, Richard Peters jumps into the welcome arms of Tony Coles at Yumanity

6 years ago

Opening new battlefront with Gilead, GSK touts new Dovato non-inferiority data months after first approval

6 years ago

KRAS G12C is the hot new play in cancer R&D, and Novartis jumps in with a combo deal

6 years ago

UK courts antibiotic developers with 'subscription-style' incentive to combat superbug scourge

6 years ago

Ex-Genentech star and 23andMe vet Richard Scheller jumps to newly public unicorn biotech BridgeBio as ‘chairman of ...

6 years ago

In a first, HKEX receives IPO pitch from local biotech looking to make it big in crowded antibodies field

6 years ago

Top Woodford lieutenant hits exit in shakeup; Roche posts more impressive data on hemophilia A drug

6 years ago

Third Rock cancer startup Revolution Medicines scores $100M in fresh raise

6 years ago

Celgene turns to Nimbus on ‘highly prized’ I/O target — landing right in Bristol-Myers’ sweet spot

6 years ago

Elias Zerhouni: Fear of ‘targeted discrimination’ against Chinese-American scientists threatens an exodus of ...

6 years ago

Trade tensions are impeding the flow of Chinese money to US biotechs — but how much?

6 years ago

Federal judge scuttles Trump's rule mandating drug prices in TV ads

6 years ago

First page Previous page 933 934 935936937 938 939 Next page Last page